Halevy Gilead discloses initial Compugen (CGEN) share and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Compugen Ltd director Halevy Gilead has filed an initial ownership report detailing existing equity awards and shareholdings. The filing lists several share options over Ordinary Shares with exercise prices ranging from $1.15 to $14.40 per share and expirations between 2028 and 2035. It also shows direct ownership of 11,407 Ordinary Shares. Footnotes state that this share figure includes 9,216 restricted stock units, with portions scheduled to vest in quarterly installments beginning on April 1, 2026 and on October 1, 2026, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Halevy Gilead
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Share Option (right to buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option (right to buy) — 35,000 shares (Direct);
Ordinary Shares — 11,407 shares (Direct)
Footnotes (1)
- Includes 9,216 restricted stock units ("RSUs"). 1,716 RSUs vest in 11 equal quarterly installments commencing on April 1, 2026; and 7,500 RSUs vest 25% on October 1, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. Fully vested. This option vested 25% on April 1, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vested 25% on October 1, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vested 25% on October 1, 2025 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. This option vests 25% on October 1, 2026 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.
FAQ
What does Halevy Gilead’s Form 3 filing for COMPUGEN LTD (CGEN) show?
The Form 3 shows Halevy Gilead’s existing holdings in Compugen, including 11,407 Ordinary Shares and multiple option grants. It establishes his baseline equity position as a director, without reporting any new purchases or sales.
What equity awards are disclosed for Halevy Gilead in the Compugen (CGEN) Form 3?
The Form 3 lists several share options over Ordinary Shares with exercise prices from $1.15 to $14.40 and expiration dates between 2028 and 2035. These options represent the right to buy Compugen shares at fixed prices.
How do Halevy Gilead’s restricted stock units in Compugen vest over time?
The filing notes 9,216 restricted stock units. Of these, 1,716 vest in 11 equal quarterly installments starting April 1, 2026, and 7,500 vest 25% on October 1, 2026 with the remainder in 12 quarterly installments, subject to continued service.
Does Halevy Gilead’s Form 3 for Compugen indicate any insider buying or selling?
No, the Form 3 functions as an initial ownership report and only shows existing holdings and awards. The transaction summary reflects holdings entries with no recorded buys, sells, exercises, gifts, or other disposition events.
What is the nature of Halevy Gilead’s ownership in Compugen securities on this Form 3?
All reported positions, including share options and Ordinary Shares, are listed as held directly. The filing does not attribute any holdings to trusts, LLCs, or other entities, and does not include disclaimers of beneficial ownership.